Tilray Brands' Potential Expansion Into the U.S. Marijuana Market Remains Uncertain
The rescheduling of medical marijuana from Schedule I to III in the U.S. is seen as positive for the cannabis industry, but it does not equate to full legalization or open access for Canadian producers like Tilray Brands (NASDAQ: TLRY) into the U.S. market. Despite a recent press release suggesting readiness for expansion, federal illegality and lack of rescheduling for recreational products mean entry remains unlikely in the near term.
